AD/PD 2022 | AMD3100 in animal models of ALS and MS

Beka Solomon, PhD, Tel Aviv University, Tev Aviv, Israel, discusses AMD3100 in animal models of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Prof. Solomon states that the overall results were positive. However, in ALS, it is only possible to reduce pathology but not cure the disease. In MS, AMD3100 has also demonstrated positive results in remyelination and the upregulation of an important transporter currently under study. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.